| Full Name | Mitchell Felder |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 41 Years |
| Location | 1 Guthrie Sq, Sayre, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891767042 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 40222 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Excela Health Westmoreland Regional Hospital | Greensburg, PA | Hospital |
| Ascension Columbia St Mary's Hospital Milwaukee | Milwaukee, WI | Hospital |
| Excela Health Latrobe Hospital | Latrobe, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Upmc Altoona Regional Health Services, Inc. | 5395659312 | 214 |
| Excela Health Physician Practices, Inc | 6204737117 | 438 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
The federal government has granted people affected by the devastating hurricanes that wracked coastal states and Puerto Rico 15 extra days to sign up for health coverage under the Affordable Care Act.
Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise.
Finding out if varicose veins warrant medical attention can be done in the comfort of your home, thanks to a service provided by UT Physicians, the clinical practice of McGovern Medical School at The University of Texas Health Science Center at Houston.
› Verified 1 days ago
| Entity Name | Upmc Altoona Regional Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396724217 PECOS PAC ID: 5395659312 Enrollment ID: O20040312000257 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
The federal government has granted people affected by the devastating hurricanes that wracked coastal states and Puerto Rico 15 extra days to sign up for health coverage under the Affordable Care Act.
Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise.
Finding out if varicose veins warrant medical attention can be done in the comfort of your home, thanks to a service provided by UT Physicians, the clinical practice of McGovern Medical School at The University of Texas Health Science Center at Houston.
› Verified 1 days ago
| Entity Name | Excela Health Physician Practices, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821225202 PECOS PAC ID: 6204737117 Enrollment ID: O20040322001393 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
The federal government has granted people affected by the devastating hurricanes that wracked coastal states and Puerto Rico 15 extra days to sign up for health coverage under the Affordable Care Act.
Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise.
Finding out if varicose veins warrant medical attention can be done in the comfort of your home, thanks to a service provided by UT Physicians, the clinical practice of McGovern Medical School at The University of Texas Health Science Center at Houston.
› Verified 1 days ago
| Entity Name | Pinnacle Health Medical Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932143427 PECOS PAC ID: 7618960493 Enrollment ID: O20040407000180 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
The federal government has granted people affected by the devastating hurricanes that wracked coastal states and Puerto Rico 15 extra days to sign up for health coverage under the Affordable Care Act.
Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise.
Finding out if varicose veins warrant medical attention can be done in the comfort of your home, thanks to a service provided by UT Physicians, the clinical practice of McGovern Medical School at The University of Texas Health Science Center at Houston.
› Verified 1 days ago
| Entity Name | Fayette Physician Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992107817 PECOS PAC ID: 3375865819 Enrollment ID: O20141211000851 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
The federal government has granted people affected by the devastating hurricanes that wracked coastal states and Puerto Rico 15 extra days to sign up for health coverage under the Affordable Care Act.
Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise.
Finding out if varicose veins warrant medical attention can be done in the comfort of your home, thanks to a service provided by UT Physicians, the clinical practice of McGovern Medical School at The University of Texas Health Science Center at Houston.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mitchell Felder, 3694 Mcconnell Rd, Hermitage, PA 16148-3208 Ph: () - | Mitchell Felder, 1 Guthrie Sq, Sayre, PA 18840-1625 Ph: (570) 882-3090 |
News Archive
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
The federal government has granted people affected by the devastating hurricanes that wracked coastal states and Puerto Rico 15 extra days to sign up for health coverage under the Affordable Care Act.
Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise.
Finding out if varicose veins warrant medical attention can be done in the comfort of your home, thanks to a service provided by UT Physicians, the clinical practice of McGovern Medical School at The University of Texas Health Science Center at Houston.
› Verified 1 days ago
Mr. Richard John Flynn, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 Fax: 570-882-3023 | |
Carlos Ynigo Dy Lopez, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-887-2838 Fax: 570-887-3192 | |
Charles R Mcgurk, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-6666 Fax: 570-882-4379 | |
Anthony L Nicotera, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-6666 Fax: 570-882-4379 | |
Dr. Paul Edward Buckthal, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 | |
Dr. Han Suk Koh, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 | |
Monique Elise Simpson, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-6666 |